Rapport surges as bipolar mania drug succeeds mid-stage trial
RAPP•Rapport Therapeutics shares rose 54.7% to $44 premarket after the company said its bipolar mania treatment RAP-219 met the main and secondary goals in a mid-stage trial. Patients had a 15.4-point mean reduction in total Young Mania Rating Scale score.
1. Trial results
Rapport Therapeutics said RAP-219 met the main and secondary goals in a mid-stage trial for bipolar mania. Patients who took the treatment had a 15.4-point mean reduction in total Young Mania Rating Scale score; all 11 items improved numerically versus placebo at week three, with irritability and disruptive-aggressive behavior reaching nominal significance.
